News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
Increasing understanding of complex tumor biology is reshaping clinical trials in the age of precision medicine, though some view these changes with concern.
The FDA granted priority review status to rucaparib for prostate cancer patients with BRCA1/2 mutations.
Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.
The worldwide license provides Iovance Biotherapeutics exclusive rights to Cellectis' TALEN gene editing technology for multiple gene targets to modify TILs for treating various cancers.